The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with high clinical and economic burden. Optimal pharmacological therapy for COPD aims to reduce symptoms and the frequency and severity of exacerbations. Umeclidinium/vilanterol (UMEC/VI) is an approved combination therapy for on...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Multidiscip Respir Med
Main Authors: Buikema, Ami R., Brekke, Lee, Anderson, Amy, Koep, Eleena, Van Voorhis, Damon, Sharpsten, Lucie, Hahn, Beth, Ray, Riju, Stanford, Richard H.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2018
Assuntos:
Original Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6180385/
https://ncbi.nlm.nih.gov/pubmed/30338068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40248-018-0151-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares